Sotac Pharmaceuticals Ltd
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
- Market Cap ₹ 136 Cr.
- Current Price ₹ 123
- High / Low ₹ 152 / 88.0
- Stock P/E 15.9
- Book Value ₹ 50.4
- Dividend Yield 0.08 %
- ROCE 15.1 %
- ROE 15.7 %
- Face Value ₹ 10.0
Pros
Cons
- Earnings include an other income of Rs.7.49 Cr.
- Debtor days have increased from 97.0 to 128 days.
- Working capital days have increased from 23.6 days to 63.0 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 28.60 | 48.84 | 76.96 | 103.75 | 96.93 | 81.40 | |
| 26.73 | 47.38 | 69.65 | 95.20 | 83.30 | 68.44 | |
| Operating Profit | 1.87 | 1.46 | 7.31 | 8.55 | 13.63 | 12.96 |
| OPM % | 6.54% | 2.99% | 9.50% | 8.24% | 14.06% | 15.92% |
| 0.22 | 0.11 | 0.93 | 0.25 | 3.90 | 7.49 | |
| Interest | 0.33 | 1.03 | 2.04 | 1.74 | 2.58 | 3.45 |
| Depreciation | 1.40 | 2.59 | 2.28 | 3.10 | 3.84 | 5.05 |
| Profit before tax | 0.36 | -2.05 | 3.92 | 3.96 | 11.11 | 11.95 |
| Tax % | 75.00% | 15.12% | 41.84% | 9.85% | 16.65% | |
| 0.09 | -2.37 | 2.29 | 3.58 | 9.28 | 8.56 | |
| EPS in Rs | 0.39 | -10.30 | 3.58 | 3.87 | 7.27 | 7.75 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | % |
| TTM: | -22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 150% |
| 3 Years: | % |
| TTM: | 88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2.30 | 2.30 | 8.05 | 11.05 | 11.05 | 11.05 |
| Reserves | 0.76 | 0.19 | 11.41 | 34.21 | 42.20 | 44.63 |
| 13.44 | 17.13 | 22.04 | 24.86 | 43.70 | 38.24 | |
| 13.89 | 15.08 | 32.14 | 35.20 | 27.37 | 29.35 | |
| Total Liabilities | 30.39 | 34.70 | 73.64 | 105.32 | 124.32 | 123.27 |
| 15.99 | 16.56 | 25.92 | 35.51 | 48.69 | 47.33 | |
| CWIP | 0.00 | 0.00 | 0.04 | 5.12 | 0.20 | 0.81 |
| Investments | 0.16 | 0.30 | 0.00 | 2.10 | 3.78 | 2.68 |
| 14.24 | 17.84 | 47.68 | 62.59 | 71.65 | 72.45 | |
| Total Assets | 30.39 | 34.70 | 73.64 | 105.32 | 124.32 | 123.27 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 0.06 | -0.31 | 8.14 | -16.08 | -4.33 | |
| -11.75 | -3.23 | -11.67 | -19.68 | -13.62 | |
| 11.40 | 3.38 | 13.14 | 29.49 | 16.09 | |
| Net Cash Flow | -0.29 | -0.16 | 9.61 | -6.26 | -1.85 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 88.83 | 43.94 | 69.91 | 92.49 | 128.44 |
| Inventory Days | 39.53 | 44.76 | 86.93 | 82.57 | 108.26 |
| Days Payable | 194.09 | 120.65 | 161.82 | 132.46 | 101.20 |
| Cash Conversion Cycle | -65.73 | -31.95 | -4.98 | 42.61 | 135.50 |
| Working Capital Days | -78.87 | -43.72 | -39.60 | 47.46 | 62.96 |
| ROCE % | -5.39% | 10.02% | 15.06% |
Documents
Announcements
-
Bagging/Receiving of orders/contracts
9 December 2025 - Cadila order Rs.1,73,55,534 for Levozet M tablets; delivery Jan 18–30, 2026.
-
Bagging/Receiving of orders/contracts
18 November 2025 - Received Letter of Acceptance for Rs27,63,89,634 supply contract; delivery by March 31, 2027.
-
Outcome of Board Meeting
12 November 2025 - Board approved HY results to Sept 30, 2025: consolidated income INR 4,129.74 lakh; profit INR 244.59 lakh.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
30 October 2025 - PCS certificate: Regulation 27(2) non-applicable for FY2025-26; listed on NSE Emerge (SME).
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
8 October 2025 - Certificate under Reg 74(5) confirming no demat/remat requests for Jul–Sep 2025.
Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.